Key result
HLHS is linked to ~260% greater risk of late adverse events in ECC Fontan recipients.
Why the study?
Factors associated with hospital and long-term outcomes after extracardiac conduit Fontan procedure were not well defined in a large binational cohort.
Cohort (n=570)
Yes
The extracardiac Fontan procedure provides excellent long-term survival, though patients with hypoplastic left heart syndrome are at higher risk for late adverse events.
Answers are grounded in this paper and cite their sources.
May warrant intensified surveillance in HLHS patients after ECC Fontan; leaves open optimal risk-stratification strategies.
OBJECTIVES: To identify factors associated with hospital and long-term outcomes in a binational cohort of extracardiac conduit (ECC) Fontan recipients. METHODS: All patients who underwent an ECC Fontan procedure from 1997 to 2010 in Australia and New Zealand were identified, and perioperative, follow-up, echocardiographic and reintervention data collected. Risk factors for early and late mortality, failure and adverse outcomes were analysed. RESULTS: A total of 570 patients were identified, and late follow-up was available in 529 patients. The mean follow-up was 6.7 years (standard deviation: 3.5) and completeness of the follow-up was 98%. There were seven hospital mortalities (1%) and 21 patients (4%) experienced early failure (death, Fontan takedown/revision or mechanical circulatory support). Prolonged length of stay occurred in 10% (57 patients), and prolonged effusions in 9% (51 patients). Overall survival at 14 years was 96% (95% confidence interval [CI]: 93-98%), and late survival for patients discharged with intact Fontan was 98% (95% CI: 94-99%). The rates of late failure (late death, transplantation, takedown, New York Heart Association class III/IV or protein-losing enteropathy) and adverse events (late failure, reoperation, percutaneous intervention, pacemaker, thromboembolic event or supraventricular tachycardia) per 100 patient-years were 0.8 and 3.8, and their 14-year freedoms were 83% (95% CI: 70-91%) and 53% (95% CI: 41-64%), respectively. After adjustment for confounders, hypoplastic left heart syndrome (HLHS) was strongly associated with prolonged effusions (OR: 2.9, 95% CI: 1.4-5.9), late failure (hazard ratio [HR]: 2.8, 95% CI: 1.1-7.5) and adverse events (HR: 3.6, 95% CI: 1.3-7.5). CONCLUSIONS: The extracardiac Fontan procedure provides excellent survival into the second decade of life, but half of patients will suffer a late adverse event by 14 years. Patients with HLHS are at higher risk of late adverse events than other morphological groups, but their survival is still excellent.
No takes yet. Share an insight, caveat, or question.
Iyengar et al. (2014) conducted a cohort in Extracardiac conduit Fontan recipients (n=570). Hypoplastic left heart syndrome (HLHS) vs. Other morphological groups was evaluated on Adverse events (HR 3.6, 95% CI 1.3-7.5). Hypoplastic left heart syndrome was strongly associated with an increased risk of late adverse events and late failure in ECC Fontan recipients.
Synapse has enriched 10 related papers. Consider them for comparative context: